Rigel Pharmaceuticals (RIGL) Treasury Shares (2021 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Treasury Shares of $67200.0 for Q1 2026, down 88.17% year-over-year from $568024.0 in Q1 2025, and down 88.94% quarter-over-quarter from $607621.0 in Q4 2025.
Rigel Pharmaceuticals (RIGL) Treasury Shares (2021 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Treasury Shares history runs 6 years deep, the most recent figure standing at $67200.0 for Q1 2026.
- In Q1 2026, Treasury Shares fell 88.17% year-over-year to $67200.0; the TTM figure through Mar 2026 stood at $67200.0 (down 88.17% YoY), while the FY2025 annual figure was $607621.0, up 56.89% from the prior year.
- Treasury Shares for Q1 2026 stood at $67200.0, down from $607621.0 in the prior quarter.
- The five-year high for Treasury Shares was $4.1 million in Q1 2024, with the low at $67200.0 in Q1 2026.
- The 5-year median for Treasury Shares is $607621.0 (2025), against an average of $1.1 million.
- The sharpest annual moves came in 2022 and 2026: Treasury Shares jumped 387.8% in 2022, then tumbled 88.17% in 2026.
- Rigel Pharmaceuticals' Treasury Shares stood at $1.1 million in 2022, then plunged by 83.15% to $185938.0 in 2023, then soared by 108.29% to $387282.0 in 2024, then surged by 56.89% to $607621.0 in 2025, then sank by 88.94% to $67200.0 in 2026.
- Business Quant data shows RIGL's Treasury Shares at $67200.0 in Q1 2026, $607621.0 in Q4 2025, and $569106.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 972,970.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 972,970.00 |
| Jun 30, 2026 | 972,970.00 |
| Mar 31, 2026 | 67,200.00 |
| Mar 31, 2026 | 67,200.00 |
| Dec 31, 2025 | 607,621.00 |
| Dec 31, 2025 | 607,621.00 |
| Sep 30, 2025 | 569,106.00 |
| Sep 30, 2025 | 569,106.00 |
| Jun 30, 2025 | 565,846.00 |
| Jun 30, 2025 | 565,846.00 |
| Mar 31, 2025 | 568,024.00 |
| Mar 31, 2025 | 568,024.00 |
| Dec 31, 2024 | 387,282.00 |
| Dec 31, 2024 | 387,282.00 |
| Sep 30, 2024 | 375,076.00 |
| Sep 30, 2024 | 375,076.00 |
| Jun 30, 2024 | 387,729.00 |
| Jun 30, 2024 | 387,729.00 |
| Mar 31, 2024 | 4.07 Mn |
| Mar 31, 2024 | 4.07 Mn |